Merus (MRUS)
(Delayed Data from NSDQ)
$59.99 USD
+15.92 (36.12%)
Updated May 24, 2024 03:59 PM ET
After-Market: $60.44 +0.45 (0.75%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Merus N.V. [MRUS]
Reports for Purchase
Showing records 81 - 100 ( 173 total )
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Register Now to Join Our Management Webinar on December 8 at 1 pm ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
SITC 2020 Abstract Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MCLA-158 Ph 1 Update By YE; Zeno Data a Go in 2Q21
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MCLA-158 Ph 1 Update By YE; Zeno Data a Go in 2Q21
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
All Eyes on eNRGy Trial Update in 2Q21; Reit Buy and $23PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
COVID-19 Pushes Expected Clinical Data Update from YE2020 to 2Q21
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
eNRGy Trial Powers Foward, Multiple Updates in 2H20; Reit Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
2Q20 - Expect Clinical Updates by the End of 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
2Q20 Financials; Zeno and MCLA-158 Updates Ahead by Year End
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Caris Collaboration Bodes Well for eNRGy Trial; Reit Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Biclonics Wage Double-Edged Attack on Cancer; Initiate With Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
EHA 2020 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D